EU/3/04/218

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2010 on request of the sponsor.

On 29 July 2004, orphan designation (EU/3/04/218) was granted by the European Commission to Innate Pharma SAS, France, for (R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate for the treatment of renal cell carcinoma.

The sponsor's name changed from Innate Pharma SAS to Innate Pharma S.A. in March 2006.

Key facts

Active substance
(R, S)-3-(bromomethyl)-3-butanol-1-yl-disphosphate
Disease / condition
Treatment of renal cell carcinoma
Date of decision
29/07/2004
Outcome
Withdrawn
Orphan decision number
EU/3/04/218

Sponsor's contact details

Innate Pharma S.A. 
Grand Pré 
119/121 ancien chemin de Cassis 
F-13009 Marseille 
France
Telephone: +33 4 96 19 05 50
Telefax: +33 4 96 19 05 55
E-mail: brailly@innate-pharma.fr

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating